← Back to Search
Does A Targeting Ligand Influence Nanoparticle Tumor Localization Or Uptake?
K. Pirollo, E. Chang
Published 2008 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Inclusion of a tumor-targeting molecule in nanosized delivery systems increases their in vivo efficacy. However, the biodistribution and pharmacokinetics of the uptake of such particles have not yet been well addressed. Several recent papers have suggested that tumor-targeting ligands function primarily to increase intracellular uptake of the nanocomplex and do not influence tumor localization. However, other reports indicate that they do play a role in the accumulation in the tumor. One difference might be the presence or absence of poly-[ethylene glycol] (PEG) in the complex and its impact on the enhanced permeability and retention (EPR) effect. Further studies are clearly needed to more fully elucidate the influence of composition on tumor-targeted, systemic delivery of nanoparticles.
This paper references
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
J. Cheng (2007)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting.
A. Iyer (2006)
Cellular dynamics of EGF receptor-targeted synthetic viruses.
K. D. de Bruin (2007)
Non-[18F]FDG PET in clinical oncology.
A. Groves (2007)
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
H. Maeda (2003)
Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer.
M. Meyer (2006)
Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
A. Hilgenbrink (2005)
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene
W. Yu (2004)
Monitoring cancer treatment with PET/CT: does it make a difference?
W. Weber (2007)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.
T. Allen (2006)
Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment
K. Pirollo (2003)
Long Circulating Poly(Ethylene Glycol)-Decorated Lipid Nanocapsules Deliver Docetaxel to Solid Tumors
M. Khalid (2006)
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
G. Sundaresan (2003)
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
D. De Paula (2007)
Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.
L. Xu (1999)
Exploiting EPR in polymer drug conjugate delivery for tumor targeting.
Sweta Modi (2006)
Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability.
C. Dass (2006)
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
A. Gabizon (2006)
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
L. Xu (2001)
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
PEGylation, successful approach to drug delivery.
F. Veronese (2005)
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles
S. Pun (2004)
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.
K. Pirollo (2006)
In Vivo Imaging of 64Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium
R. Rossin (2008)
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
S-D Li (2006)
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers.
E. Garanger (2007)
Vector Targeting for Therapeutic Gene Delivery
D. Curiel (2002)
Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system
Sajid. Hussain (2007)
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
A. Wu (2000)
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas.
Yue Cao (2006)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
Recent developments and future trends in nuclear medicine instrumentation.
H. Zaidi (2006)
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
L. Xu (2002)
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide.
Wei Yu (2004)
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
T. R. Daniels (2006)
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Chao Fang (2006)
Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
K. Pirollo (2007)
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
R. Kircheis (2001)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
Pharmacokinetic Consequences of Pegylation
M. Hamidi (2006)
This paper is referenced by
Tumor therapy: targeted drug delivery systems.
L. Dai (2016)
Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles
M. Wang (2013)
Newer Developments in the Nanoparticles for Cancer Treatment.
N. Patel (2014)
Nanoparticles' interactions with vasculature in diseases.
J. K. Tee (2019)
Immune cells as tumor drug delivery vehicles.
F. Combes (2020)
From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.
Sarah R MacEwan (2017)
Physics in nanomedicine: Phenomena governing the in vivo performance of nanoparticles
Lucas A Lane (2020)
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.
Nazila Kamaly (2012)
Chapter 2 Improved Targeting of Cancers with Nanotherapeutics
Christian Foster (2018)
One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Chien-Han Kao (2014)
Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels.
A. Mikhail (2009)
A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density
B. Gray (2013)
Gold-silica quantum rattles for cancer therapy and diagnosis
Mathew Hembury (2012)
Nanotechnology for Cancer Treatment: Possibilities and Limitations
Joseph W. Nichols (2013)
Design considerations for nanotherapeutics in oncology.
T. Stylianopoulos (2015)
EDTA capped iron oxide nanoparticles magnetic micelles: drug delivery vehicle for treatment of chronic myeloid leukemia and T1–T2 dual contrast agent for magnetic resonance imaging
E. Shah (2016)
Enhanced Solubility and Targeted Delivery of Drugs using Cucurbit[n]uril-Type Compounds
G. Hettiarachchi (2013)
Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Denzil Furtado (2018)
Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
Shahrzad Amiri Darban (2018)
Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy
L. Liu (2014)
Nanotechnology: A possible healer in drug delivery system
NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?
Sten Friberg (2016)
pH-sensitive polymers for drug delivery
K. Huh (2012)
Title Pharmacokinetic considerations for targeted drug delivery
F. Yamashita (2016)
Progress of nanoparticles research in cancer therapy and diagnosis
I. Negut (2017)
Nanotechnology: A Tool to Enhance Therapeutic Values of Natural Plant Products
A. Kumari (2012)
LETHAL WEAPONS - Novel approaches for receptor-targeted cancer cell elimination
Emilia Peuhu (2010)
FACULTY OF PHYSICS ADAM MICKIEWICZ UNIVERSITY NANOBIOMEDICAL CENTRE DEPARTMENT OF MEDICAL PHYSICS POZNAŃ Synthesis and evaluation of superparamagnetic iron oxide nanoparticles containing doxorubicin as a potential targeted drug delivery system
Magdalena Hałupka (2015)
Reduction breakable cholesteryl pullulan nanoparticles for targeted hepatocellular carcinoma chemotherapy.
Huanan Li (2014)
Nanocarriers for drug delivery applications
M. Chamundeeswari (2018)
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems
P. Karmali (2011)
Characterizing Topology of Surface Ligands on Liposomes
S. Lee (2018)See more